Evidence map›Paper›PMID 25450719›Full record

ArticleJournal of hepatology2015

Dietary effects on liver tumor burden in mice treated with the hepatocellular carcinogen diethylnitrosamine.

Marin E Healy, Jenny D Y Chow, Frances L Byrne, David S Breen, Norbert Leitinger, Chien Li, Carolin Lackner, Stephen H Caldwell, Kyle L Hoehn

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Marin E HealyDepartment of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA.
Jenny D Y ChowDepartment of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA.
Frances L ByrneDepartment of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA.
David S BreenDepartment of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA.
Norbert LeitingerDepartment of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA.
Chien LiDepartment of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA.
Carolin LacknerInstitute of Pathology, Medical University of Graz, Graz, Austria.
Stephen H CaldwellDepartment of Medicine, University of Virginia, Charlottesville, VA 22908, USA; Emily Couric Clinical Cancer Center, University of Virginia, Charlottesville, VA 22908, USA.
Kyle L HoehnDepartment of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA; Department of Medicine, University of Virginia, Charlottesville, VA 22908, USA; Emily Couric Clinical Cancer Center, University of Virginia, Charlottesville, VA 22908, USA; School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, Australia. Electronic address: klh8st@virginia.edu.
University of Virginia · USMedical University of Graz · ATUNSW Sydney · AU

Funding

Cancer Research Training Program: From Molecular Mechanisms to Therapeutic StrategiesT32CA009109 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Andrew Carl Dudley, Melanie R Rutkowski · 1985 to 2026
$13.9M
ACC enzymes and protein acetylationR01DK101803 · NIDDK · UNIVERSITY OF VIRGINIA · PI HOEHN, KYLE LEE · 2014 to 2017
$1.4M
Role of Dab2 in Fatty Liver DiseaseR01DK096076 · NIDDK · UNIVERSITY OF VIRGINIA · PI LEITINGER, NORBERT · 2013 to 2016
$1.4M
Lipid Metabolism in Ethanol-Stimulated Liver CancerR21AA022154 · NIAAA · UNIVERSITY OF VIRGINIA · PI HOEHN, KYLE LEE · 2014 to 2015
$409k
NCI NIH HHS T32 CA009109NIAAA NIH HHS R21 AA022154NIDDK NIH HHS R01 DK096076NIDDK NIH HHS R01 DK101803
6 · The paper itself

Abstract

BACKGROUND &

aimsMice exposed to the hepatocellular carcinogen diethylnitrosamine at 2 weeks of age have a high risk of developing primary liver tumors later in life. Previous studies have demonstrated that diethylnitrosamine-treated mice have increased tumor burden when fed an obesigenic "Western" diet rich in lard fat and sugar. However, the role of dietary fats vs. sugars in the promotion of liver cancer is poorly understood. The aim of this study was to determine how altering dietary fats vs. sugars affects tumor burden in the diethylnitrosamine model.

methodsC57BL/6N mice were treated with diethylnitrosamine at 2 weeks of age and, from 6 to 32 weeks of age, fed one of five diets that differed in fat and sugar content, including normal chow, ketogenic, and Western diets.

resultsMice fed sugar-rich diets had the greatest tumor burden irrespective of dietary fat content. In contrast, mice fed a high-fat low-sugar diet had the least tumor burden despite obesity and glucose intolerance. When evaluated as independent variables, tumor burden was positively correlated with hepatic fat accumulation, postprandial insulin, and liver IL-6, and inversely correlated with serum adiponectin. In contrast, tumor burden did not correlate with adiposity, fasting insulin, or glucose intolerance. Furthermore, mice fed high sugar diets had lower liver expression of p21 and cleaved caspase-3 compared to mice fed low sugar diets.

conclusionsThese data indicate that dietary sugar intake contributes to liver tumor burden independent of excess adiposity or insulin resistance in mice treated with diethylnitrosamine.

Indexed as

AdipokinesAdiposityAnimalsCarcinogensDietary CarbohydratesDietary FatsDiethylnitrosamineDiet, KetogenicDiet, WesternFemaleInflammation MediatorsInsulin ResistanceLiverLiver Neoplasms, ExperimentalMaleMiceAdipokinesCarcinogensDietary CarbohydratesDietary FatsDiethylnitrosamineInflammation MediatorsFructoseInflammationInsulin resistanceLiver cancerObesitySugar

Identifiers

PMID25450719
PMCPMC4336610
OpenAlexW1964245978

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.